Stockreport

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients w...

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF Significant Unmet Need Remains in this SettingOver 14,000 Patients are Eligible for 2L+ Treatment in This Setting in the United States Each YearSummit Enters 2026 with A [Read more]